Indenza (Enzalutamide 40 Mg) by Aprazer healthcare

Indenza 40 mg (Enzalutamide) Indenza (Enzalutamide 40 Mg) by Aprazer healthcare

Aprazer healthcare Aprazer Healthcare Private Limited, incorporated in 2017 in India, is a pharmaceutical company dedicated to offering highquality and affordable medicines to healthcare professionals and patients. Specializing in life-saving drugs, Aprazer focuses on therapeutic segments such as Oncology, Hepatology, Gastroenterology, and HIV. the company ensures the manufacturing and sale of therapeutic medicines that meet global standards. Aprazer prioritizes customer needs and emphasizes trust-building with healthcare professionals and patients. Their commitment to safety is evident through the addition of security seals on all packaging, providing a sense of security to customers. Furthermore, their Braille-friendly packaging promotes inclusivity and effective communication with visually impaired individuals.

01

Indenza 40 mg The peculiar properties of Indenza 40 mg (Enzalutamide) that help in slowing down the growth of prostate cancer can be described in points as follows: 1. Inhibits communication: Enzalutamide obstructs the communication tool of cancer cells by binding to the androgen receptor (AR) and disrupting the signaling pathway.

2. Suppresses growth: It hinders the unwanted growth of androgens, specifically testosterone, which fuels the growth of prostate cancer cells.

3. Induces cell death: Enzalutamide promotes the process of apoptosis, causing cancer cells to self-destruct.

4. Reduces risk: By targeting the androgen receptor, Enzalutamide reduces the risk of disease progression.

5. Delays chemotherapy: The use of Enzalutamide may postpone the need for chemotherapy by effectively managing the disease progression.

Indenza 40 mg The Indenza 40mg capsule is formulated with Enzalutamide as its active component, falling under the class of drugs recognized as androgen receptor inhibitors. This pharmaceutical is prescribed for managing advanced prostate cancer in individuals who exhibit unresponsiveness to surgical or hormonal interventions.

It is imperative to refrain from consuming these capsules if one has a known allergy to any of their constituents. Throughout the course of treatment, physicians may periodically conduct Prostatespecific antigen (PSA) tests. This medical examination assesses the PSA level, a protein generated by the prostate gland, which can become elevated in men suffering from prostate cancer. PSA levels serve as valuable indicators to monitor disease progression and treatment effectiveness. Additional evaluations encompass liver function tests and complete blood count (CBC) to avert potential serious complications.

Patients with a history of seizures should exercise caution when considering this medication, as it has the potential to induce seizures. Furthermore, it is advisable to abstain from consuming grapefruit or grapefruit juice while using this drug, as they can augment the drug's concentration in the body. For pregnant individuals, this medication is contraindicated, as it can harm the developing fetus and induce fertility issues. Therefore, it is imperative to communicate any fertility concerns with the healthcare provider prior to initiating treatment with this medication. In cases of individuals contemplating pregnancy, it is advisable for both men and women to adhere to appropriate contraceptive methods during the treatment course and for three months following the final administration of Indenza 40mg capsules.

Side-effects of Indenza 40 mg (Enzalutamide):

01

Tiredness (Fatigue)

02

Pain in the back, muscles, bones and joints

03

Diarrhea

04

Weakness in the muscles

05

Swelling (edema) in the hands and legs

06

Severe headache

When should Indenza 40 mg (Enzalutamide) be avoided or used cautiously?

1.If patients have a history of or experience sudden unwarranted changes in behaviour caused due to disturbances in the brain 2. If patients are confirmed with symptoms like headache, impaired vision and low blood pressure 3. If patients are seen with kidney diseases 4. If patients show signs of severe disease of the liver 5. If patients are seen with a relative risk of heart diseases 6.If patients are allergic to dosage and show symptoms like tongue, lip, or pharyngeal swelling (edema) 7. If patients are intolerant to lactose

Thanks Do you have any questions? info@aprazerhealthcare.com (+91) 7792-959-295 www.aprazerhealthcare.com

CREDITS: This presentation template was created by Slidesgo, and includes icons by Flaticon and infographics & images by Freepik

Please keep this slide for attribution